Caliber Biotherapeutics announced the opening of the world’s largest plant-made pharmaceutical manufacturing facility in Bryan, Texas, with the capability of producing 10 million to 100 million doses of infectious vaccines per month, and hundreds of thousands of doses of protein biotherapeutics such as monoclonal antibodies.
In addition to its plant-based facility, Caliber will also develop a proprietary product pipeline for cancer and infectious diseases utilizing cell- and microbial-based production systems.
“With plant-based systems, we have an unprecedented level of flexibility and scalability,” says Barry Holtz, PhD, Caliber’s chief scientific officer. “This enables simultaneous production of multiple proteins and rapid change-overs from one product to another in order to meet patients’ needs and respond to emerging infectious diseases and bioterror threats.”
“The Caliber platform is designed to be uniquely agile and responsive, enabling us to accelerate development of products with improved efficacy, reduced cost and enhanced safety,” says Brett Giroir, MD, Chief Medical Officer. “Our goal is to make a rapid, meaningful impact on patients with unmet medical needs, both in the United States as well as in lesser developed countries with profound public health challenges.”
Release Date: April 25, 2011
Source: Caliber Biotherapeutics